KAPA
Kairos Pharma, Ltd.KAPA
KAPA
About: Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.35% more ownership
Funds ownership: 0% [Q2] → 0.35% (+0.35%) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
470%
upside
Avg. target
$9
470%
upside
High target
$9
470%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 37% 1-year accuracy 72 / 196 met price target | 470%upside $9 | Buy Maintained | 22 Jan 2025 |
Financial journalist opinion
Based on 3 articles about KAPA published over the past 30 days
Neutral
Business Wire
1 day ago
Kairos Pharma Provides Business Update and Outlook into 2025
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key 2024 milestones and outlook into 2025 in a Letter to Shareholders: Dear Kairos Pharma Shareholders, The management team and Board of Directors of Kairos Pharma Ltd. are pleased to provide you with a brief update on the state of business and noteworthy milestones of 20.
Neutral
Business Wire
2 weeks ago
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, and Neil Bhowmick, Chief Scientific Officer, will present a corporate overview at the Lytham Partners Investor Healthcare Summit. The conference is being held virtually on January 13, 2025. Event: Lytham Partners Investor Healthcare Summit Presentation Date: Monday, January 13, 2025 Time: 2:00 PM ET Webcast Link: http.
Positive
Seeking Alpha
3 weeks ago
Kairos Pharma: Potential To Remove Resistance With Established Drugs
ENV-105 targets CD105 proteins to restore sensitivity in cancer cells, enhancing the efficacy of existing therapies like ERLEADA and TAGRISSO. Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025. Financially, Kairos Pharma may need to raise funds by early 2025, leveraging positive interim data to boost stock prices.
Neutral
Accesswire
1 month ago
Kairos Pharma to Participate in The Microcap Conference in January 2025
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
Neutral
Business Wire
1 month ago
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients. City of Hope Cancer Center is the first of several planned new centers to be added in the coming weeks to support the Company.
Neutral
GlobeNewsWire
1 month ago
IBN Initiates Coverage of Kairos Pharma Ltd.
LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to spearhead its corporate communications efforts.
Neutral
GlobeNewsWire
3 months ago
Kairos Pharma to Present at the LD Micro Main Event XVII
LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Neutral
GlobeNewsWire
3 months ago
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit where he will be speaking with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.
Neutral
GlobeNewsWire
3 months ago
Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of companion biomarkers for Kairos Pharma's cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma's Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105.
Positive
Seeking Alpha
4 months ago
U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost
Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition, respectively. Seven IPOs and three SPACs submitted initial filings. Eight companies are expected to price their IPOs in the upcoming week, including three larger deals.
Charts implemented using Lightweight Charts™